The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Progesterone Receptor in Non–Small Cell Lung Cancer—A Potent Prognostic Factor and Possible Target for Endocrine Therapy
Abstract
A possible involvement of gender-dependent factors has been postulated in development of human non–small-cell lung cancers (NSCLC), but its details remain unclear. In this study, we examined biological significance of progesterone receptor in NSCLCs. Progesterone receptor immunoreactivity was detected in 106 of 228 NSCLCs (46.5%). Progesterone receptor–positive NSCLC was frequently detected in female and adenocarcinoma, and was inversely associated with tumor-node-metastasis stage and histologic differentiation. Progesterone receptor status was also associated with better clinical outcome of the patients, and a multivariate analysis revealed progesterone receptor status as an independent prognostic factor. Progesterone-synthesizing enzymes were detected in NSCLCs, and tissue concentration of progesterone was higher in these cases (n = 42). Immunoblotting analyses showed the presence of progesterone receptor in three NSCLC cell lines (A549, LCSC#2, and 1-87), but not in RERF-LC-OK or PC3. Transcriptional activities of progesterone receptor were increased by progesterone in these three progesterone receptor–positive NSCLC cells by luciferase assays. Cell proliferation was inhibited by progesterone in these progesterone receptor–positive NSCLC cells in a dose-dependent manner, which was inhibited by progesterone receptor blocker. Proliferation of these tumor cells injected into nude mice was also dose-dependently inhibited by progesterone, with a concomitant increase of p21 and p27 and a decrease of cyclin A, cyclin E, and Ki67. Results of our present study suggested that progesterone receptor was a potent prognostic factor in NSCLCs and progesterone inhibited growth of progesterone receptor–positive NSCLC cells. Therefore, progesterone therapy may be clinically effective in suppressing development of progesterone receptor–positive NSCLC patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Progestin regulation of cellular proliferation.
CLARKE, C. L., & SUTHERLAND, R. L. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-266 · Cited by 650 · cited 1×
“In contrast, progesterone generally promotes differentiation and inhibits cellular proliferation through the progesterone receptor (5).”
BackgroundEndocrine treatment of breast cancer in women
SANTEN, R. J., MANNI, A., HARVEY, H., & REDMOND, C. (1990) · Endocrine Reviews · doi:10.1210/edrv-11-2-221 · Cited by 399 · cited 2×
“Progesterone treatment is an established endocrine therapy in human hormone-dependent breast (9) and endometrial cancers (40), and at present, oral progestins such as medroxyprogesterone acetate are widely employed.”
BackgroundRecent Trends in Lung Cancer Mortality in the United States
Jemal, A., Chu, K. C., & Tarone, R. E. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.4.277 · Cited by 167
Cited by
It's all about sex: gender, lung development and lung disease
Carey, M. A., Card, J. W., Voltz, J. W., Arbes, S. J., Germolec, D. R., Korach, K. S., & Zeldin, D. C. (2007) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2007.08.003 · Cited by 417
Sex differences and sex steroids in lung health and disease
Townsend, E. A., Miller, V. M., & Prakash, Y. S. (2012) · Endocrine Reviews · doi:10.1210/er.2010-0031 · Cited by 395
Progesterone Is Essential for Maintenance and Growth of Uterine Leiomyoma
Ishikawa, H., Ishi, K., Serna, V. A., Kakazu, R., Bulun, S. E., & Kurita, T. (2010) · Endocrinology · doi:10.1210/en.2009-1225 · Cited by 362
Impact of Age, Sex, and Comorbidity on Cancer Therapy and Disease Progression
Pal, S. K., & Hurria, A. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0579 · Cited by 265
Mas, A., Cervelló, I., Gil-Sanchis, C., Faus, A., Ferro, J., Pellicer, A., & Simón, C. (2012) · Fertility and Sterility · doi:10.1016/j.fertnstert.2012.04.044 · Cited by 104
Metadata
- Authors
- Ishibashi, H., Suzuki, T., Suzuki, S., Niikawa, H., Lu, L., Miki, Y., Moriya, T., Hayashi, S.-I., Handa, M., Kondo, T., & Sasano, H.
- Venue
- Cancer Research
- Published
- 2005-07-15
- Volume
- 65
- Issue
- 14
- Pages
- 6450-6458
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2103192143
- Cited by
- 177
- References
- 3
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Progesterone Receptor in Non–Small Cell Lung Cancer—A Potent Prognostic Factor and Possible Target for Endocrine Therapy. https://app.cochat.ai/papers/10.1158/0008-5472.can-04-3087
- The paper
- Ishibashi, H., Suzuki, T., Suzuki, S., Niikawa, H., Lu, L., Miki, Y., Moriya, T., Hayashi, S.-I., Handa, M., Kondo, T., & Sasano, H. (2005). Progesterone Receptor in Non–Small Cell Lung Cancer—A Potent Prognostic Factor and Possible Target for Endocrine Therapy. Cancer Research. https://doi.org/10.1158/0008-5472.can-04-3087
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.